Adagene (ADAG) Non-Current Debt (2019 - 2026)
Adagene (ADAG) posted quarterly Non-Current Debt of $1138.2 billion for Q4 2025, up 172.72% year-over-year from $417.3 billion in Q4 2024, and up 172.72% quarter-over-quarter from $417.3 billion in Q4 2024.
Adagene (ADAG) Non-Current Debt (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Non-Current Debt for 7 consecutive years, with $1138.2 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 172.72% year-over-year to $1138.2 billion; the TTM figure through Dec 2025 stood at $1138.2 billion (up 172.72% YoY), while the FY2025 annual figure was $1138.2 billion, up 172.72% from the prior year.
- Non-Current Debt grew to $1138.2 billion in Q4 2025 per ADAG's latest filing, from $417.3 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $14146.5 billion in Q4 2022 and bottomed at $2.0 million in Q2 2021.
- Historically, Non-Current Debt has averaged $5761.2 billion across 5 years, with a median of $1138.2 billion in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 472839123.1% — and 2024, when it slumped 100.0%.
- Adagene's Non-Current Debt stood at $3.0 million in 2021, then soared by 472839123.1% to $14146.5 billion in 2022, then dropped by 4.29% to $13540.0 billion in 2023, then slumped by 96.92% to $417.3 billion in 2024, then jumped by 172.72% to $1138.2 billion in 2025.
- Business Quant data shows ADAG's Non-Current Debt at $1138.2 billion in Q4 2025, $417.3 billion in Q4 2024, and $4.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1,138.17 Bn |
| Dec 31, 2024 | 417.34 Bn |
| Jun 30, 2024 | 4.56 Mn |
| Dec 31, 2023 | 13,540.03 Bn |
| Jun 30, 2023 | 13,348.00 Bn |
| Dec 31, 2022 | 14,146.54 Bn |
| Jun 30, 2022 | 9,260.36 Bn |
| Dec 31, 2021 | 2.99 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Dec 31, 2020 | 2.97 Mn |
| Dec 31, 2019 | 1.52 Mn |